VCIM
CNTX icon

Velan Capital Investment Management’s Context Therapeutics CNTX Stock Holding History

Velan Capital Investment Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$262K Hold
100,000
– – 0.16% 32
2025
Q4 		$147K Hold
100,000
– – 0.09% 38
2025
Q3 		$96.9K Hold
100,000
– – 0.09% 44
2025
Q2 		$65.5K Buy
100,000
+10,000
+11% +$7.19K 0.06% 42
2025
Q1 		$55.1K Hold
90,000
– – 0.06% 36
2024
Q4 		$94.5K Sell
90,000
-1,200,323
-93% -$2.08M 0.08% 27
2024
Q3 		$2.53M Hold
1,290,323
– – 2.36% 8
2024
Q2 		$2.59M Buy
+1,290,323
New +$2.22M 1.48% 10

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Velan Capital Investment Management's CNTX Position: Q1 2026 in Review

Velan Capital Investment Management held its Context Therapeutics (CNTX) position steady in Q1 2026 at 100,000 shares worth $262K. The position accounts for 0.16% of the portfolio, ranked #32.

Velan Capital Investment Management first reported a position in CNTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.59M in Q2 2024. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Velan Capital Investment Management held 100,000 shares of Context Therapeutics worth $262K as of Q1 2026.
  • Velan Capital Investment Management left its Context Therapeutics share count unchanged in Q1 2026.
  • Context Therapeutics made up 0.16% of Velan Capital Investment Management's portfolio in Q1 2026, its #32 holding.
  • Velan Capital Investment Management first reported a position in Context Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Velan Capital Investment Management's Context Therapeutics position peaked at $2.59M in Q2 2024.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.